Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flu-M Vaccine Tolerability, Safety and Immunogenicity
NCT05312294Phase 3Completed
- Sponsor
- Saint Petersburg Scientific Research Institute of Vaccines and Serums
- Start
- Dec 2020
- Primary completion
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen in influenza, sponsored by Saint Petersburg Scientific Research Institute of Vaccines and Serums. Started Dec 2020; status: completed.
02
Drugs
Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05312294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05312294.